食管切除术后辅助化疗时机对生存的影响
基于美国国家癌症数据库2004至2015年1634例pT1-4aNxM0食管癌患者,分析食管切除术后辅助化疗起始时机与生存的关系。多因素分析显示延迟超过45天与生存劣势无关,结论认为辅助化疗时机不影响生存,应个体化决策。
要点
- 食管切除术后辅助化疗中位起始时间为59天(四分位距45-78天)。
- 延迟超过45天启动辅助化疗与 inferior 生存无关,连续变量分析亦支持。
核心结论
- 食管切除术后辅助化疗的起始时机似乎不影响生存。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2004至2015年接受辅助化疗(伴或不伴放疗)的pT1-4aNxM0食管癌患者,共1634例。
主要发现
- 中位至辅助化疗时间为59天(四分位距45-78天)。
- 45天内接受辅助化疗者中位生存29个月,其他时间点接受者中位生存28个月。
- 多因素分析显示延迟超过45天启动辅助化疗与生存劣势无关。
- 将至辅助化疗时间作为连续变量分析,风险比为1.0(95%CI 1.0-1.0)。
关键数值与推荐
- 辅助化疗起始时间按四分位分为4组,中位时间为59天(四分位距45-78天)。
- 延迟超过45天与生存劣势无关,连续变量风险比1.0(95%CI 1.0-1.0)。
临床怎么用
- 鉴于食管切除术后恢复过程高度可变,辅助化疗启动决策应经多学科讨论并个体化制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant chemotherapy (AC) after esophagectomy improves survival in esophageal cancer when induction therapy is not given; however, the optimal timing for initiation of AC is poorly characterized. We aimed to determine the impact of timing of AC on survival after esophagectomy. METHODS: The National Cancer Database was queried for patients with pT1-4aNxM0 esophageal cancer receiving AC with or without radiation from 2004 to 2015. The median and interquartile range of time to AC were determined. Patients were stratified by initiation of AC into 4 cohorts based on quartiles. Kaplan-Meier curves were generated and factors associated with survival were identified by Cox proportional hazards modeling. A separate analysis was performed with time to AC as a continuous variable. RESULTS: A total of 1634 patients received AC after esophagectomy. Median time to receipt of AC was 59 (interquartile range, 45-78) days. There was no significant difference in overall survival at 5 years (P = .86) between groups. Median survival was 29 months in those receiving AC within 45 days and was 28 months in those receiving AC at other time points. On multivariable analysis, delay in receipt of AC beyond 45 days was not associated with inferior survival. This was preserved when time to AC was analyzed as a continuous variable (hazard ratio, 1.0; 95% confidence interval, 1.0-1.0). CONCLUSIONS: Timing of initiation of AC after esophagectomy does not appear to impact survival. Given the highly variable postoperative course after esophagectomy, the decision to start AC should involve multidisciplinary discussion and be made on a patient-by-patient basis.
引用
- Rhodin KE, Raman V, Jawitz OK, et al. The Effect of Timing of Adjuvant Therapy on Survival After Esophagectomy. Ann Thorac Surg. 2020. PMID: 32330471. doi:10.1016/j.athoracsur.2020.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。